Corporate, Commercial & Regulatory

Impressive depth of specialised experience

Van Bael & Bellis advises multinational clients on corporate, commercial and regulatory issues in the EU and Belgium.

Discover our expertise
  • "The lawyers are excellent; very responsive and to the point."

    Chambers Europe

Latest news

Sign up for updates
    • 13/02/2019
    • News

    Thibaut D’hulst and Darach Connolly quoted by Politico on the recent German Bundeskartellampt decision on Facebook

    Van Bael & Bellis counsel Thibaut D’hulst and associate Darach Connolly were quoted by Politico on the recent Facebook decision by the German competition authority – the Bundeskartellampt – which links data protection and competition law in a novel decision.

    Read more
    • 04/02/2019
    • News

    Van Bael & Bellis promotes Thibaut D’hulst

    Van Bael & Bellis is pleased to announce the promotion of data protection, IT and IP specialist Thibaut D’hulst to Counsel. Thibaut joined Van Bael & Bellis in 2006. He assists clients in ensuring compliance with the EU General Data Protection Regulation (GDPR) and also focuses on intellectual property, pharmaceutical law and competition law. Thibaut commented on his promotion: “My journey at Van Bael & Bellis has been filled with inspirational people and valuable learning experiences. I am grateful to my colleagues and to the partnership for this recognition and look forward to continuing to advance our practice.” Thibaut’s promotion within Van Bael & Bellis is recognition of the firm’s commitment to focus on new areas of growth, whilst maintaining their leading reputation in the areas of competition and international trade. Co-managing partners, Jean-François Bellis and Philippe De Baere commented: Van Bael and Bellis is a client-driven firm which has always brought in the talent necessary to provide the quality services our clients expect. Thibaut has developed a unique expertise in helping our clients structure their businesses in a compliant way that optimises the policy space under the EU’s rules on data protection and intellectual property. Van Bael & Bellis’ Brussels and Geneva offices now include 22 partners, 6 senior counsel, 6 counsel and 34 associates.

    Read more
    • 31/01/2019
    • News

    Andreas Reindl participates in panel session at the Competition Law Nordic conference in Stockholm

    On 30 January 2019, Van Bael & Bellis partner Andreas Reindl participated as a panel member in a session on Vertical Restraints and Distribution: Practical Considerations on the second day of the Competition Law Nordic conference in Stockholm. The other members of the panel were Camilla Robstad (Orkla), Åsa Ericson Hedström (Fiskars Group) and Henrik Okholm (Copenhagen Economics). Further information on the conference is available here.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]

Recommendations

  • The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

    Chambers Europe
  • Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

    Legal 500
  • They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

    IFLR1000
  • They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

    Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

Get in touch with our Corporate, Commercial & Regulatory teams today

Recent publications

Sign up for updates
    • 19/02/2019
    • Newsletters

    VBB on Belgian Business Law, Volume 2019, No. 01

    The January 2019 issue of our Belgian Business Law newsletter reporting on the latest developments in a range of areas, including competition, data protection, intellectual property and labour law. Please click below to read the issue.

    Read more
    • 18/02/2019
    • Articles

    Belgium - Bill regarding Reimbursement of Pharmaceutical Specialties

    On 7 February 2019, the federal government submitted a bill regarding the reimbursement of pharmaceutical specialties to the federal chamber of representatives (Bill 54 3535/001) (the “Bill”). The Bill provides for the following saving measures designed to contain the pharmaceutical budget: • More significant price decrease on the basis of turnover for medicines that have benefited from reimbursement for 15 years (“volume cliff”) (There will be a staggered system providing for a range of turnover figures between EUR 1.5 million and EUR 70 million). • Extension of maximum price (“ceiling price”) system from medicines delivered in the community pharmacy to medicines delivered in the hospital pharmacy. • Start of cheapest prescriptions and prescription quota systems in hospital environment. • Further limitation of invoicing level open to hospitals to 85% of the official price. This system applies to a segment of the medicines open to competition, namely medicines falling under the reference reimbursement system. It is designed to channel to the public purse part of the savings made by hospitals from discounts obtained from their suppliers. • Adaptation of definition of “cheap prescription”. • Medicines in reimbursement category F will now also be made subject to the price cuts applying to “old” medicines (reimbursed for 12 or 15 years). The reimbursement basis of medicines of category F is a flat fee per indication, treatment or analysis. • Definition of specific compensating levy for 2019 (“compenserende heffing”/”cotisation compensatoire”). • Limited increase of pricing transparency for medicines subject to Managed Entry Agreements: Members of the General Council (the top body within the Public Institute for Illness and Disability Insurance) and of the Auditing Court (which verifies and oversees the spending of the government) will be given access to aggregated price information (as a rule on the ATC1 level, i.e., the top level of the Anatomical Therapeutic Chemical Classification System of medicines). The qualifying members will be required to sign a non-disclosure agreement. The government is apparently confident that the Bill will garner a majority in the chamber. The Bill can be found here:

    Read more
    • 14/02/2019
    • Articles

    Overview of the EU’s Single-Use Plastics Directive

    This client alert provides an overview of the EU’s forthcoming “Directive on the reduction of the impact of certain plastic products on the environment”, otherwise known as the single-use plastics Directive. The Directive is expected to enter into force in late spring or early summer 2019 and will have a major impact on the future of the EU plastics market. It is important for both traders and manufacturers to understand how their businesses may be affected as the requirements of the Directive are phased in over the next two to five years.

    Read more
Keep updated Sign up for VBB insights

Be the first amongst your peers to get the latest publications and insights in Corporate, Commercial & Regulatory law.